HALOZYME THERAPEUTICS INC (HALO) Fundamental Analysis & Valuation

NASDAQ:HALO • US40637H1095

70.36 USD
+0.96 (+1.38%)
Last: Mar 4, 2026, 02:48 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This HALO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to HALO. HALO was compared to 520 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make HALO suitable for value and quality investing!


Dividend Valuation Growth Profitability Health

8

1. HALO Profitability Analysis

1.1 Basic Checks

  • HALO had positive earnings in the past year.
  • HALO had a positive operating cash flow in the past year.
  • In the past 5 years HALO has always been profitable.
  • In the past 5 years HALO always reported a positive cash flow from operatings.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

1.2 Ratios

  • HALO has a better Return On Assets (12.55%) than 94.42% of its industry peers.
  • With an excellent Return On Equity value of 649.18%, HALO belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 25.65%, HALO belongs to the top of the industry, outperforming 98.27% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for HALO is in line with the industry average of 18.99%.
  • The 3 year average ROIC (20.76%) for HALO is below the current ROIC(25.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROIC 25.65%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • With an excellent Profit Margin value of 22.69%, HALO belongs to the best of the industry, outperforming 94.23% of the companies in the same industry.
  • HALO's Profit Margin has declined in the last couple of years.
  • HALO has a Operating Margin of 58.45%. This is amongst the best in the industry. HALO outperforms 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of HALO has grown nicely.
  • HALO has a Gross Margin of 83.62%. This is amongst the best in the industry. HALO outperforms 86.73% of its industry peers.
  • In the last couple of years the Gross Margin of HALO has remained more or less at the same level.
Industry RankSector Rank
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. HALO Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HALO is creating value.
  • HALO has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, HALO has less shares outstanding
  • The debt/assets ratio for HALO is higher compared to a year ago.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 3.94 indicates that HALO is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of HALO (3.94) is better than 69.62% of its industry peers.
  • The Debt to FCF ratio of HALO is 6.00, which is on the high side as it means it would take HALO, 6.00 years of fcf income to pay off all of its debts.
  • HALO has a Debt to FCF ratio of 6.00. This is amongst the best in the industry. HALO outperforms 91.35% of its industry peers.
  • A Debt/Equity ratio of 43.89 is on the high side and indicates that HALO has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 43.89, HALO is doing worse than 82.12% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Altman-Z 3.94
ROIC/WACC3.43
WACC7.47%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 4.66 indicates that HALO has no problem at all paying its short term obligations.
  • HALO has a Current ratio (4.66) which is in line with its industry peers.
  • A Quick Ratio of 3.66 indicates that HALO has no problem at all paying its short term obligations.
  • HALO has a Quick ratio (3.66) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.66
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. HALO Growth Analysis

3.1 Past

  • HALO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.36%.
  • HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 35.63% yearly.
  • HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.55%.
  • The Revenue has been growing by 39.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.28% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 5.67% on average over the next years.
EPS Next Y101.78%
EPS Next 2Y54.48%
EPS Next 3Y35.8%
EPS Next 5Y17.28%
Revenue Next Year26.89%
Revenue Next 2Y19.59%
Revenue Next 3Y12.37%
Revenue Next 5Y5.67%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. HALO Valuation Analysis

4.1 Price/Earnings Ratio

  • HALO is valuated rather expensively with a Price/Earnings ratio of 17.04.
  • Compared to the rest of the industry, the Price/Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 94.81% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.83. HALO is valued slightly cheaper when compared to this.
  • HALO is valuated reasonably with a Price/Forward Earnings ratio of 8.44.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 97.88% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of HALO to the average of the S&P500 Index (24.95), we can say HALO is valued rather cheaply.
Industry RankSector Rank
PE 17.04
Fwd PE 8.44
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaper than 95.77% of the companies in the same industry.
  • 95.00% of the companies in the same industry are more expensive than HALO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 23.19
EV/EBITDA 11.23
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HALO has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as HALO's earnings are expected to grow with 35.80% in the coming years.
PEG (NY)0.17
PEG (5Y)0.48
EPS Next 2Y54.48%
EPS Next 3Y35.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HALO Dividend Analysis

5.1 Amount

  • HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HALO Fundamentals: All Metrics, Ratios and Statistics

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (3/4/2026, 2:48:01 PM)

70.36

+0.96 (+1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-04
Inst Owners105.85%
Inst Owner Change-19.83%
Ins Owners0.81%
Ins Owner Change0.73%
Market Cap8.27B
Revenue(TTM)1.40B
Net Income(TTM)316.89M
Analysts76
Price Target86.19 (22.5%)
Short Float %11.87%
Short Ratio7.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.57%
Min EPS beat(2)-110.7%
Max EPS beat(2)3.56%
EPS beat(4)3
Avg EPS beat(4)-18.27%
Min EPS beat(4)-110.7%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)-1.32%
EPS beat(12)9
Avg EPS beat(12)0.23%
EPS beat(16)12
Avg EPS beat(16)2.67%
Revenue beat(2)2
Avg Revenue beat(2)1.65%
Min Revenue beat(2)1.13%
Max Revenue beat(2)2.18%
Revenue beat(4)4
Avg Revenue beat(4)6.95%
Min Revenue beat(4)1.13%
Max Revenue beat(4)12.81%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.56%
PT rev (1m)9.56%
PT rev (3m)13.34%
EPS NQ rev (1m)-13.18%
EPS NQ rev (3m)-15.58%
EPS NY rev (1m)-0.27%
EPS NY rev (3m)2.43%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)-5.22%
Revenue NY rev (1m)3.94%
Revenue NY rev (3m)7.24%
Valuation
Industry RankSector Rank
PE 17.04
Fwd PE 8.44
P/S 5.92
P/FCF 23.19
P/OCF 12.7
P/B 169.51
P/tB N/A
EV/EBITDA 11.23
EPS(TTM)4.13
EY5.87%
EPS(NY)8.33
Fwd EY11.84%
FCF(TTM)3.03
FCFY4.31%
OCF(TTM)5.54
OCFY7.87%
SpS11.88
BVpS0.42
TBVpS-12.87
PEG (NY)0.17
PEG (5Y)0.48
Graham Number6.21
Profitability
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROCE 34.76%
ROIC 25.65%
ROICexc 27.31%
ROICexgc 93.59%
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
FCFM 25.55%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
ROICexc(3y)25.83%
ROICexc(5y)35.19%
ROICexgc(3y)78.99%
ROICexgc(5y)74.81%
ROCE(3y)28.13%
ROCE(5y)25.85%
ROICexgc growth 3Y19.79%
ROICexgc growth 5YN/A
ROICexc growth 3Y19.91%
ROICexc growth 5YN/A
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Debt/EBITDA 2.37
Cap/Depr 334.74%
Cap/Sales 21.1%
Interest Coverage 71.42
Cash Conversion 72.05%
Profit Quality 112.6%
Current Ratio 4.66
Quick Ratio 3.66
Altman-Z 3.94
F-Score5
WACC7.47%
ROIC/WACC3.43
Cap/Depr(3y)121.97%
Cap/Depr(5y)85.12%
Cap/Sales(3y)8%
Cap/Sales(5y)5.01%
Profit Quality(3y)116.88%
Profit Quality(5y)108.21%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
EPS Next Y101.78%
EPS Next 2Y54.48%
EPS Next 3Y35.8%
EPS Next 5Y17.28%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%
Revenue Next Year26.89%
Revenue Next 2Y19.59%
Revenue Next 3Y12.37%
Revenue Next 5Y5.67%
EBIT growth 1Y48.02%
EBIT growth 3Y41.29%
EBIT growth 5Y41.42%
EBIT Next Year40.15%
EBIT Next 3Y22.4%
EBIT Next 5Y3.88%
FCF growth 1Y-23.82%
FCF growth 3Y14.89%
FCF growth 5Y46.43%
OCF growth 1Y36.01%
OCF growth 3Y39.48%
OCF growth 5Y63.66%

HALOZYME THERAPEUTICS INC / HALO FAQ

Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 7 / 10 to HALO.


Can you provide the valuation status for HALOZYME THERAPEUTICS INC?

ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.


Can you provide the profitability details for HALOZYME THERAPEUTICS INC?

HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.


What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?

The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 7 / 10.


Can you provide the expected EPS growth for HALO stock?

The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 101.78% in the next year.